CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 245 enrolled
Drug / intervention
CAB-AXL-ADC +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03425279
NCT03425279Phase 2Completed
CompareCT.gov

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

BioAtla, Inc.·interventional·Posted Feb 7, 2018·Updated Sep 23, 2025

In Brief

A Phase 2 clinical trial evaluating CAB-AXL-ADC and PD-1 inhibitor for Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma. Completed, enrolled 245 participants across 40 sites in 3 countries.

Detailed Summary

The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUndifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
CountriesHong Kong, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 7, 2018
Enrollment StartFeb 15, 2018
Primary CompletionJan 8, 2025
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 8.4 years ago

Interventions

CAB-AXL-ADCbiological

Conditionally active biologic anti-AXL antibody drug conjugate

PD-1 inhibitorbiological

PD-1 inhibitor